Garenoxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Garenoxacin
Accession Number
DB06160
Type
Small Molecule
Groups
Investigational
Description

Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]

Structure
Thumb
Synonyms
  • desquinolone
External IDs
T-3811
Product Ingredients
IngredientUNIICASInChI Key
Garenoxacin MesylateOXI6EF55FR223652-90-2IGTHEWGRXUAFKF-NVJADKKVSA-N
Categories
UNII
V72H9867WB
CAS number
194804-75-6
Weight
Average: 426.42
Monoisotopic: 426.139113458
Chemical Formula
C23H20F2N2O4
InChI Key
NJDRXTDGYFKORP-LLVKDONJSA-N
InChI
InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
IUPAC Name
1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O

Pharmacology

Indication

Investigated for use/treatment in bacterial infection.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Garenoxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Garenoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Garenoxacin.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Garenoxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Garenoxacin.Approved, Experimental, Investigational
AcenocoumarolGarenoxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Garenoxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Garenoxacin.Approved
AlbiglutideGarenoxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Garenoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Garenoxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
AlogliptinGarenoxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Garenoxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Garenoxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Garenoxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Amiodarone.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Garenoxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Garenoxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Garenoxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Garenoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Garenoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Garenoxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Garenoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Garenoxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Garenoxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Garenoxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Garenoxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Garenoxacin.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Garenoxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Garenoxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Garenoxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Garenoxacin.Approved
BromocriptineGarenoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Garenoxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Garenoxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Garenoxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Garenoxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Garenoxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Garenoxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinGarenoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Garenoxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Garenoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Garenoxacin.Approved
ChloroquineChloroquine may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Chlorphenamine.Approved
ChlorpropamideGarenoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Garenoxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Garenoxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Garenoxacin.Approved, Investigational
ClemastineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Garenoxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Garenoxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Garenoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Garenoxacin.Approved
ClorindioneGarenoxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Garenoxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Garenoxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Garenoxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Garenoxacin.Experimental
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Garenoxacin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Garenoxacin.Approved, Investigational
DelamanidGarenoxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Garenoxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Garenoxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Garenoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Garenoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Garenoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Garenoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Garenoxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Garenoxacin.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
DicoumarolGarenoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Garenoxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Garenoxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Garenoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Garenoxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Garenoxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Garenoxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Garenoxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Garenoxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Dimenhydrinate.Approved
DiphenadioneGarenoxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Garenoxacin.Approved, Investigational
DisopyramideGarenoxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Garenoxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Garenoxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
DulaglutideGarenoxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Garenoxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Garenoxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Garenoxacin.Investigational
EmpagliflozinGarenoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Garenoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Garenoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Garenoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Garenoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Garenoxacin.Approved
EthenzamideEthenzamide may increase the neuroexcitatory activities of Garenoxacin.Experimental
Ethyl biscoumacetateGarenoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ExenatideGarenoxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Garenoxacin.Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Garenoxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Garenoxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Garenoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Garenoxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Garenoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Garenoxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Garenoxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Garenoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Garenoxacin.Approved, Investigational
FluindioneGarenoxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Garenoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Garenoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Garenoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Garenoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Garenoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Garenoxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Garenoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Garenoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Garenoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Garenoxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Garenoxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Garenoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Garenoxacin.Approved, Investigational, Withdrawn
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Garenoxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Garenoxacin.Experimental
GliclazideGarenoxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Garenoxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Garenoxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Garenoxacin.Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Garenoxacin.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Garenoxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Garenoxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Garenoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Garenoxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Garenoxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Garenoxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Garenoxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Garenoxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Garenoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Garenoxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Garenoxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
Insulin AspartGarenoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGarenoxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Garenoxacin.Approved
Insulin GlulisineGarenoxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Garenoxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Garenoxacin.Approved
IronThe serum concentration of Garenoxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Garenoxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Garenoxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Garenoxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Garenoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Garenoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Garenoxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Garenoxacin.Experimental
Lanthanum carbonateThe serum concentration of Garenoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Garenoxacin.Approved, Investigational
LiraglutideGarenoxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Garenoxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Garenoxacin.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Loratadine.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Garenoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Garenoxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Garenoxacin.Investigational
MecaserminGarenoxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Garenoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Garenoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Garenoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Garenoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Garenoxacin.Approved
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Garenoxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Garenoxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Garenoxacin.Approved, Investigational
MifepristoneGarenoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolGarenoxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Garenoxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Garenoxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Garenoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Garenoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Garenoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
NateglinideGarenoxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Garenoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Garenoxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Garenoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Garenoxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Garenoxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Garenoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Garenoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Garenoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Garenoxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Garenoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Garenoxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Garenoxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Garenoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Garenoxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PentamidineGarenoxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Garenoxacin.Experimental
PhenindioneGarenoxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Garenoxacin.Approved
PhenprocoumonGarenoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Garenoxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PioglitazoneGarenoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
PramlintideGarenoxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Garenoxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Garenoxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Garenoxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Garenoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Garenoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Garenoxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Garenoxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Garenoxacin.Experimental
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Garenoxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Garenoxacin.Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Garenoxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Garenoxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Quetiapine.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinineGarenoxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideGarenoxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Garenoxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Garenoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Garenoxacin.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Garenoxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Garenoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Garenoxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Garenoxacin.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Garenoxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Garenoxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Garenoxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Garenoxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Garenoxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Garenoxacin.Investigational
Strontium ranelateThe serum concentration of Garenoxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Garenoxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineGarenoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleGarenoxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
SulfisoxazoleGarenoxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
SunitinibGarenoxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Garenoxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Garenoxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Garenoxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Garenoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Garenoxacin.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Terodiline.Experimental
TheophyllineThe metabolism of Theophylline can be decreased when combined with Garenoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Garenoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Garenoxacin.Investigational
TioclomarolGarenoxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Garenoxacin.Approved, Withdrawn
TolazamideGarenoxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideGarenoxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Garenoxacin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Garenoxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Garenoxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Garenoxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Garenoxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Garenoxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Valproic Acid.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Garenoxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Garenoxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Garenoxacin.Approved
WarfarinGarenoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
110579
ChEBI
131716
ChEMBL
CHEMBL215303
Wikipedia
Garenoxacin
ATC Codes
J01MA19 — Garenoxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0232 mg/mLALOGPS
logP1.71ALOGPS
logP1.62ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.87 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity110.37 m3·mol-1ChemAxon
Polarizability42.39 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Isoindolines / Isoindoles / Aralkylamines / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Amino acids
show 10 more
Substituents
Quinoline-3-carboxylic acid / Dihydroquinolone / Dihydroquinoline / Isoindoline / Isoindole / Isoindole or derivatives / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aralkylamine / Benzenoid
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Drug created on March 19, 2008 10:14 / Updated on August 15, 2018 13:34